Alto Neuroscience (ANRO) Stock News, Apr-Aug 2025

Alto Neuroscience (NYSE:ANRO) reported Q2 2025 financial results and pipeline updates. The company acquired ALTO-207, a potentially best-in-class dopamine agonist combination product for treatment-resistant depression (TRD), with a planned Phase 2b pivotal trial expected by mid-2026. Alto maintains a strong cash position of $148.1 million, expected to fund operations into 2028 and through four upcoming clinical readouts.

Key pipeline developments include ongoing trials for ALTO-101 in schizophrenia (topline data 2H 2025), ALTO-300 in major depressive disorder (data mid-2026), and ALTO-100 in bipolar depression (data 2H 2026). Q2 2025 financial results showed R&D expenses of $13.1 million and a net loss of $17.7 million.

Alto Neuroscience (NYSE:ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has appointed Dr. Raymond Sanchez to its Board of Directors effective August 12, 2025.

Dr. Sanchez brings over 20 years of strategic experience in life sciences and currently serves as Senior Advisor at Bain Capital Life Sciences. His extensive background includes roles as Chief Medical Officer at Cerevel Therapeutics and senior positions at Otsuka Pharmaceutical. The appointment comes as Alto prepares to initiate its potentially pivotal Phase 2b trial of ALTO-207.

A psychiatrist by training and former Chief Resident at Yale School of Medicine, Dr. Sanchez's expertise in CNS drug development aligns with Alto's mission to revolutionize neuropsychiatric treatment through precision medicine approaches.

Alto Neuroscience (NYSE: ANRO) announced the publication of the PAX-D study results in The Lancet Psychiatry, evaluating pramipexole for treatment-resistant depression (TRD). The study, conducted by the University of Oxford and funded by the UK's National Institute for Health and Care Research, demonstrated significant clinical benefits.

The study showed that pramipexole augmentation of antidepressant treatment at a 2.5mg target dose achieved a large reduction in symptoms (Cohen's d=0.87) compared to placebo at 12 weeks, although it was associated with high adverse effects. These findings informed Alto's acquisition of ALTO-207, a fixed-dose combination of pramipexole and ondansetron, designed to maintain efficacy while reducing side effects.

Alto plans to initiate a potentially pivotal Phase 2b trial of ALTO-207 by mid-2026, collaborating with the National Health Service and PAX-D clinical sites. The company aims to leverage its proprietary dopamine biomarker insights in depression to optimize the treatment approach.

Alto Neuroscience (NYSE:ANRO) has announced positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept trial of ALTO-203, a novel oral histamine H3 inverse agonist for major depressive disorder (MDD) patients. The trial successfully identified a biomarker (EEG theta/beta ratio) for patient selection and demonstrated the drug's pro-cognitive and wake-promoting effects.

Key findings include significant improvements in sustained attention (p0.05 at 25µg dose), confirmed by wearable devices (p0.05 at 25µg; p<0.001 at 75µg), and improvements in the MADRS score (2 points at week 3 for 25µg dose). The study enrolled and showed ALTO-203 was well-tolerated, with insomnia being the most common side effect.

Alto Neuroscience (NYSE: ANRO) has acquired a novel dopamine agonist portfolio from Chase Therapeutics Corporation, including ALTO-207 (formerly CTC-501) for treatment resistant depression (TRD). ALTO-207 is a fixed-dose combination of pramipexole and ondansetron, designed to provide rapid antidepressant effects while reducing adverse events. The drug showed significant positive results in a Phase 2a study, demonstrating greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05). Alto plans to initiate a potentially pivotal Phase 2b trial by mid-2026, with topline data expected in 2027. The acquisition adds a major late-stage clinical readout without affecting Alto's current cash runway, which extends into 2028. The company's strategic focus on dopamine biomarkers in depression positions them to advance this therapeutic approach for TRD patients.

Alto Neuroscience (NYSE: ANRO) presented data at the 2025 ASCP Annual Meeting regarding ALTO-300 (agomelatine) for Major Depressive Disorder (MDD). The presentation highlighted the drug's safety profile and biomarker validation. ALTO-300 is being developed as a 25mg adjunctive treatment for MDD patients with a specific EEG biomarker. The drug acts as a melatonin agonist and 5-HT2C antagonist. Key findings include: - The 25mg dose shows similar antidepressant efficacy to 50mg while avoiding liver enzyme elevation concerns - Phase 2a trial (239 patients) reported no significant liver function test elevations - Most common side effect was headache - Ongoing Phase 2b trial shows favorable safety profile - Preclinical and clinical evidence supports the mechanistic link between ALTO-300 and its EEG biomarker for patient selection While agomelatine is approved in Europe and Australia at both 25mg and 50mg doses, it remains unapproved in the United States.

Alto Neuroscience (NYSE: ANRO), a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, has announced its participation in two major investor conferences in June 2025. The company will present at the Jefferies Global Healthcare Conference (June 3-5) in New York, featuring a fireside chat on June 5 at 2:00 pm ET. Additionally, Alto will participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference (June 16-17) with an on-demand presentation available from June 17 at 7:00 am ET. Both events will include one-on-one investor meetings, and presentations will be accessible via webcast on Alto's website.

Alto Neuroscience (NYSE: ANRO) reported Q1 2025 financial results and pipeline updates. The company maintains a strong cash position of $161.3 million, expected to fund operations into 2028. Key clinical trials progress includes: ALTO-203 for major depressive disorder (MDD) with topline data expected in Q2 2025, ALTO-101 for schizophrenia in H2 2025, ALTO-300 Phase 2b trial in MDD with data expected mid-2026, and ALTO-100 for bipolar depression with results in H2 2026. Q1 2025 financial results showed R&D expenses of $10.0 million, G&A expenses of $5.7 million, and a net loss of $15.2 million. The company's biomarker-driven approach in neuropsychiatric drug development continues to advance with new data presentations supporting their precision medicine strategy.

Alto Neuroscience (NYSE: ANRO) presented significant findings at the Society of Biological Psychiatry Annual Meeting 2025, highlighting advancements in their precision psychiatry pipeline. The company successfully identified and validated an EEG-based biomarker for predicting placebo response in major depressive disorder (MDD) patients, potentially improving clinical trial efficiency.

Key developments include:

• Validation of EEG biomarker's ability to predict placebo response in MDD trials, with significant correlations in ALTO-100 Phase 2b and EMBARC sertraline trials
• New mechanistic insights linking ALTO-300's action to EEG biomarker patterns through 5-HT2C antagonism and dopamine regulation
• Positive results from ALTO-101's preclinical rescue study, demonstrating its potential for treating cognitive impairment in schizophrenia
• ALTO-203 showed promise in reversing anhedonia-like behavior in preclinical studies